WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555346

CAS#: 1383450-81-4

Description: JNJ-53718678, also known as JNJ-678, is a fusion inhibitor with selective activity against RSV.

Chemical Structure

CAS# 1383450-81-4

Theoretical Analysis

MedKoo Cat#: 555346
Name: JNJ-53718678
CAS#: 1383450-81-4
Chemical Formula: C21H20ClF3N4O3S
Exact Mass: 500.0897
Molecular Weight: 500.9212
Elemental Analysis: C, 50.35; H, 4.02; Cl, 7.08; F, 11.38; N, 11.18; O, 9.58; S, 6.40

Price and Availability

Size Price Availability Quantity
200.0mg USD 1250.0 2 Weeks
500.0mg USD 1950.0 2 Weeks
1.0g USD 2950.0 2 Weeks
2.0g USD 5250.0 2 Weeks
Bulk inquiry

Synonym: JNJ-53718678; JNJ 53718678 JNJ53718678; JNJ-678; JNJ 678; JNJ678;

IUPAC/Chemical Name: 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one


InChi Code: InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3

SMILES Code: O=C(N1CC(F)(F)F)N(CC(N2CCCS(=O)(C)=O)=CC3=C2C=CC(Cl)=C3)C4=C1C=CN=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 500.9212 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Stevens M, Rusch S, DeVincenzo J, Kim YI, Harrison L, Meals EA, Boyers A,
Fok-Seang J, Huntjens D, Lounis N, Mari N K, Remmerie B, Roymans D, Koul A,
Verloes R. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers
Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect
Dis. 2018 Jul 24;218(5):748-756. doi: 10.1093/infdis/jiy227. PubMed PMID:

2: Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein
P, Rigaux P, Berg JVD, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S,
Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson
P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A. Therapeutic
efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug
1;8(1):167. doi: 10.1038/s41467-017-00170-x. PubMed PMID: 28761099; PubMed
Central PMCID: PMC5537225.

3: Korell J, Green B, DeVincenzo J, Huntjens D. A human challenge model for
respiratory syncytial virus kinetics, the pharmacological effect of a novel
fusion inhibitor, and the modelling of symptoms scores. Eur J Pharm Sci. 2017 Nov
15;109S:S154-S160. doi: 10.1016/j.ejps.2017.05.070. Epub 2017 Jun 9. PubMed PMID:

4: Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, Rusch S, Stevens M, Verloes R.
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for
the Treatment of Respiratory Syncytial Virus: Results from a Phase I,
Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy
Adult Subjects. Clin Pharmacokinet. 2017 Nov;56(11):1331-1342. doi:
10.1007/s40262-017-0522-8. PubMed PMID: 28238203.


10.0mg / Not available

Additional Information

Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today.